Skip to Content
COVID-19 Resources
NCI Formulary
Contact NExT
Show menu
Search this site
Last Updated: 01/25/17

Information below provided by the Pharmaceutical Company.

Bristol-Myers Squibb (www.bms.com) External Link

Company Bio:

Bristol-Myers Squibb (BMS) has a vision for the future of cancer care that is focused on Immuno- Oncology, now considered a major treatment choice alongside surgery, radiation, chemotherapy and targeted therapies for certain types of cancer.

BMS has a comprehensive clinical portfolio of investigational and approved Immuno-Oncology agents, many of which were discovered and developed by their scientists. The ongoing Immuno-Oncology clinical program at BMS is looking at broad patient populations, across multiple solid tumors and hematologic malignancies, and lines of therapy and histologies, with the intent of powering trials for overall survival and other important measures like durability of response. BMS pioneered the research leading to the first regulatory approval for the combination of two Immuno-Oncology agents and continue to study the role of combinations in cancer.

BMS is also investigating other immune system pathways in the treatment of cancer including CTLA-4, CD-137, KIR, SLAMF7, PD-1, GITR, CSF1R, IDO and LAG-3. These pathways may lead to potential new treatment options — in combination or monotherapy — to help patients fight different types of cancers. Collaboration with academia, as well as small and large biotech and pharmaceutical companies, to research the potential of Immuno-Oncology and non-Immuno-Oncology combinations helps BMS to achieve their goal of providing new treatment options in clinical practice.

Bristol-Myers Squibb is committed to changing survival expectations in hard-to-treat cancers and the way patients live with cancer.

Available Agents